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ABSTRACT 
Title:   To compare control in a group of insulin-requiring Type-2 diabetic patients before 
and after the implementation of specialist-supervised care.  
Objective:  To evaluate and compare any differences in control, i.e. HbA1C, total 
cholesterol, BP and BMI in a single group of Type-2 diabetes patients during two time 
periods, i.e. before and after specialist-supervised care.  In addition, to describe 
differences in the use of anti-platelet and statin therapy for primary cardiovascular 
prophylaxis. 
Methods: Patients were recruited from the Diabetes Clinic at Chris Hani Baragwanath 
Academic Hospital (CHBAH) and the audits of two separate time periods were 
conducted.  The first audit recorded standard of care delivered by registrars from January 
2005 to December 2007.  The second audit recorded care after the introduction of 
specialist-supervised care from September 2009 to September 2012.  The patients were 
all insulin-requiring and were required to be seen for at least 24 months during both audit 
periods.  The first recorded HbA1C in (i) 2005 and (ii) from September 2009 triggered the 
inception of a patient’s assessment periods.  Data for at least 80% of parameters had to 
be available for a patient to be included in the audit.   
Results: This study showed significant differences using ANCOVA comparing final 
values for each audit after adjustment for their respective baseline values in respect of 
HbA1C (p<0.000), SBP (p<0.012) and BMI (p<0.001) after the implementation of an 
endocrinologist-supervised clinic.  The percentage of patients reaching guideline targets, 
and the use of aspirin and statins, improved as well.   
Conclusion:  This study showed a difference in the level of care delivered by the 
endocrinologist-supervised clinic as opposed to one which was led by registrars.  
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However, other factors may have contributed to the outcomes, most notably that the 
consultation time with each patient was longer after the introduction of expert supervision 
in 2009. 
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CHAPTER 1 
1.0 BACKGROUND LITERATURE ANALYSIS AND CRITIQUE 
Type-2 diabetes is a multifactorial disease with a strong polygenic and environmental 
component, notably obesity.  Obesity is thought to be the primary cause of Type-2 
diabetes in people who are genetically predisposed to the disease (Rosenbaum et al., 
1997).  Over the past decade South Africa (SA) has been burdened by a rising prevalence 
in both communicable and non-communicable diseases. In particular, the prevalence of 
Type-2 diabetes is rising in both rural and urban areas. The high health and economic 
burden associated with this disease necessitates an urgent need to implement disease 
prevention strategies and improve diabetes-care in the population (Mayosi et al., 2009). 
Type-2 diabetes mellitus is a metabolic disorder characterized by high blood glucose in 
the context of insulin resistance and relative insulin deficiency. This is in contrast to Type-
1 diabetes mellitus, an autoimmune disease, in which there is an absolute insulin 
deficiency due to the autoimmune destruction of islet cells in the pancreas. Type-2 
diabetes constitutes about 90% of cases, the other 10% being primarily due to Type-1 
diabetes mellitus, gestational diabetes and some rare inheritable forms.  
1.1 Prevalence of Type-2 diabetes 
In the 21st century the prevalence of Type-2 diabetes is approaching epidemic proportions, 
with a world-wide prevalence estimated to be as high as 8.3% and a further 6.4% having 
impaired glucose tolerance (IGT) (Bertram et al., 2013).  Strikingly, 50% of people 
remain undiagnosed, with recent figures showing between 77.9% and 80.0% being 
undiagnosed in Africa’s low- and middle-income countries respectively (Bertram et al., 
2013).   In 2011, 366 million people world-wide were affected by diabetes, compared to 
approximately 30 million in 1985, a 12 fold increase. The rising prevalence of diabetes 
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mirrors the increase in the prevalence of obesity (Beckles et al., 2011). Type-2 diabetes 
is common in both the developed and developing countries (Bertram et al., 2013). 
The National Diabetes Fact Sheet reported that the United States of America (USA) now 
has an estimated 25.8 million Type-2 diabetic patients, 18.8 million of whom are 
diagnosed, and approximately 7 million undiagnosed. They further report another 79 
million people to have pre-diabetes.  In the USA 1.9 million new cases are diagnosed per 
year in people aged 20 and older. It is estimated that by the end of 2030, 552 million 
people will suffer from Type-2 diabetes world-wide, 80% of whom will be from the low 
and middle income countries (Murray, 2009, Whiting et al., 2011). 
It is estimated that sub-Saharan Africa currently has 12 million Type-2 diabetic patients 
with a regional prevalence of 3.8% (Figure 1). This is expected to double in the next 
decade.  Within Africa, Southern Africa is estimated to have one of the highest 
prevalence’s of diabetes (Murray, 2009). 
 
Figure 1 Prevalence rates of Type-2 diabetes in different countries in Africa (Murray, 
2009) 
In SA, it is estimated that Type-2 diabetes affected 2-3 million people prior to 2006 (Soma 
and Rheeder, 2006).  The estimated prevalence of Type-2 diabetes in SA in 2000 was 
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5,5% but this had  increased to 9% by 2006.  As many as 80% of people with diabetes in 
Southern Africa remain undiagnosed (Bertram et al., 2013, Soma and Rheeder, 2006). 
The prevalence of diabetes among Black South Africans in Cape Town in 2009 was, 
12.1% in males and 13.1% in females respectively (Peer et al., 2012).  This was the first 
study to demonstrate that urban Black South Africans had a significantly higher 
prevalence of diabetes compared to a decade ago. Erasmus et al found a much higher 
prevalence (28.2%) of Type-2diabetes among the mixed ancestry (coloured) population 
of the Western Cape (Erasmus et al., 2012). Despite concerted efforts on the part of 
government and healthcare providers worldwide, this condition remains under-diagnosed 
(Beckles et al., 2011). 
Within SA there are marked differences in the prevalence of Type-2 diabetes between 
rural and urban populations (Bertram et al., 2013). Of South Africans living with diabetes, 
65% reside in urban areas and 35% in rural areas. The higher urban prevalence can be 
explained by a more unhealthy diet, lack of physical exercise and more sedentary forms 
of employment. The differences in prevalence of Type-2 diabetes in urban and rural areas 
in South Africa is shown in Figure 2. 
 
Figure 2.  Differences in prevalence of Type-2 diabetes in rural and urban males and 
females in South Africa (Bertram et al., 2013). 
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1.2 Aetiology of Type-2 diabetes 
The causes of Type-2 diabetes are multi-factorial and include both genetic and 
environmental elements that affect beta-cell function and insulin sensitivity in muscle, 
liver, adipose tissue and pancreas. Twin studies suggest a strong genetic contribution for 
the risk of Type-2 diabetes (Florez et al., 2003).  The general risk world-wide is 5-10% 
and increases to 40% if a first degree relative has Type-2 diabetes (Meigs et al., 2000, 
Weijnen et al., 2002).  The risk is also influenced by race and ethnicity e.g. Pima Indians 
have a risk of 40 to 50% in adults over the age of 35, Mauritians of Indian origin up to 
30%, and South African Indians up to 13% (Knowler et al., 1993, King and Rewers, 1993, 
Soderberg et al., 2005, Omar et al., 1994). 
Genetic susceptibility, however, only accounts for a portion of the risk to developing 
diabetes. Lifestyle factors, such as lack of physical exercise, obesity, and access to high 
dense calorie foods contribute to the risk of developing diabetes.  Hallal et.al. reported 
that 31.1% of adults are physically inactive world-wide, ranging from 17% in South-East 
Asia to as high as 43% in the Americas (Hallal et al., 2012). 
Insulin resistance is the major determinant of hyperglycaemia, and obesity is probably 
the most important factor in the development of insulin resistance.  The increase in 
prevalence of Type-2 diabetes in SA parallels the rise in obesity (Figure 3). In South 
African male adolescents obesity rates have doubled from 1.6% to 3.3%, and 5% to 7.5% 
in female adolescents from 2002 to 2006 (Reddy et al., 2012). The rates of obesity are 
lower in rural than in urban youth. One of the reasons to account for the differences in 
prevalence of obesity between rural versus urban populations is differences in diet.  The 
diets of people living in rural areas tend to be higher in unrefined carbohydrates and fibre, 
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and lower in saturated fats and sugars, corresponding to the more traditional way of eating 
(Reddy et al., 2012, Kiawi et al., 2006, Pretorius, 2013). 
Pretorius et al. stated from their work “With urbanisation their diet has changed to a more 
westernised diet with a resultant decrease in carbohydrates and fibre and an increase in 
fat, processed food and salt consumption”(Pretorius, 2013). The poor diet and lack of 
physical exercise contribute to the increasing rates of obesity.  In addition, cultural issues 
such as the perception that “obesity is a sign of good living”, keeps the incidence of 
obesity high. In the context of hunger and deprivation, obesity confers respect and 
affluence (Kiawi et al., 2006). 
 
Figure 3. The body mass index of males and females in an urban African township in the 
Cape Town metropolitan area showing high rates of obesity (BMI>30) (Case and 
Menendez, 2009) 
 
There is also an association between risk of Type-2 diabetes and environmental factors, 
such as small particulate air pollution and endocrine disruptors (Remillard and Bunce, 
2002, Pearson et al., 2010). 
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1.3 Chronic complications and mortality 
Chronic uncontrolled diabetes is complicated by macro- and micro-vascular disease. 
Studies suggest that approximately 50% of Type-2 diabetic patients will have macro- or 
micro-vascular complications at diagnosis and these complications progress with disease 
duration (UKPDS, 2012). In SA, it is estimated that 115,000 new cases of Type-2 diabetes 
develop each year, as well as 7,800 cases of visual impairment due to retinopathy and 
2,100 patients requiring foot or toe amputations(Bertram et al., 2013). 
 
Table 1. The modelled incidence of Type-2 diabetes and the incidence of retinopathy and 
amputations in SA (Bertram et al., 2013) 
 
 
Mortality data in SA diabetic patients has not been accurately reported. However, 
diabetes, heart disease and stroke are the next most significant causes of death following 
that due to the human immunodeficiency virus (HIV) infection (Bradshaw et al., 2003). 
Data from Statistics South Africa, for 1999-2006, shows a sustained increase in death 
from diabetes (38%). (see Fig. 4) 
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Figure 4.  Death rates per 100 000 from certain non-communicable diseases in males and 
females in South Africa, 1999-2006 (Mayosi et al., 2009). 
 
1.4 Factors influencing the complications of diabetes 
Factors influencing the complications of diabetes include duration of disease, glycaemic 
control, hypertension, dyslipidaemia and smoking (Klein, 1995). 
The United Kingdom Prospective Diabetes Study (UKPDS) showed an upward trend in 
HbA1C in both conventionally- and intensively- treated groups. Furthermore, there was a 
correlation between poor glycaemic control and complication rates. The UKPDS also 
showed a 37% risk reduction of microvascular complication for every percentage point 
reduction in HbA1C. Good blood pressure (BP) control showed that lowering the pressure 
to a mean of 144/82mmHg significantly decreased the risk of strokes, diabetes related 
deaths, heart failure, microvascular complications and visual loss (UKPDS, 1998, 
Stratton et al., 2000).  Parving et al. showed that even modest control of hypertension also 
had a beneficial effect on the rate of decline in glomerular filtration rate (Parving et al., 
1983).  The myocardial infarction hazard ratio was 0.84 (p=0.052) (in the intensive arm 
of the UKPDS), with a reduction in 16% for every percentage point reduction in HbA1C. 
This result was, however, statistically not significant (Holman et al., 2008). 
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The Heart Protection Study and Collaborative Atorvastatin Diabetes Study (CARDS) 
showed that diabetic patients benefit from statin use and that this is independent of their 
baseline levels of low density lipoprotein (LDL) (Collins et al., 2003, Colhoun et al., 
2004).  Cohen et al. have shown in black patients with a PCSK9 mutation that there is a 
88% reduction in CVD risk as a result of the low LDL cholesterol (Cohen et al., 2006). 
This implies that any drop in LDL, irrespective of cause, may also benefit  Southern 
African Black patients who have, to date, not been widely studied in a large primary 
prevention study.   
Bariatric surgery is a good indicator that weight loss lowers glycaemia in Type-2 diabetes 
and, in the majority of cases, reverses the diabetes (Pories et al., 1995). Thus, weight 
management is paramount in improving glycaemia and decreasing the rate of 
complications.   
Lastly, anti-platelet therapy has been shown to significantly reduce the first event of 
coronary heart disease (odds ratio, 0.72 [95% CI, 0.9 to ]) and ischaemic stroke in diabetic 
patients (Hayden et al., 2002).  The use of low dose aspirin as primary prophylaxis is well 
documented (De Berardis et al., 2009). 
 
1.5 Economic impact of Type-2 diabetes 
The cost of treatment and morbidity as a result of diabetes mellitus carry an enormous 
economic burden. Data from the 2011 National Diabetes Fact Sheet showed that in 2007 
the total deaths relating to diabetes in the USA were 231,404.  The cost of treatment of 
diabetic patients in the USA, in 2007, was $174 billion, $116 billion for direct medical 
costs and the balance as indirect costs (i.e. disability and work loss). The health 
expenditure in 2011 amounted to $465 million which accounted for 11% of the total 
health budget in the USA (Whiting et al., 2011).  The cost burden of diabetes on the South 
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African economy has as yet not been established, but is likely to be high in keeping with 
data from other countries. Figure 5 below estimates cost where South Africa has been 
placed in Group 1.  The three groups were determined based on gross national income 
per capita expressed in purchasing power parity (PPP) for 2005.  Group 1 had a PPP 
≥$8000 (Kirigia et al., 2009). 
 
Figure 5 shows the estimated cost where South Africa has been placed in group 1 (Kirigia 
et al., 2009) 
 
1.6 Diabetes Guidelines 
The landmark studies in Type 1 diabetes, the Diabetes Control and Complication Trial 
(DCCT) and the Stockholm Diabetes Intervention Study; and those in Type-2 diabetes, 
the UKPDS and the Kumamoto Study, helped to establish glycaemic goals of therapy to 
improve long-term outcome in Type-1 and Type-2 diabetes (Turner et al., 1998, DCCT-
Group, 1993, Reichard et al., 1988, Shichiri et al., 2000). The South African guidelines 
established by the Society for Endocrinology, Metabolism and Diabetes of South Africa 
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(SEMDSA) are in line with those of the American Diabetes Association (ADA).  The 
major recommendations are that:  
a) HbA1C be done every 3 to 6 months 
b) A dilated-eye examination and urinary microalbumin assessment, annually 
c) Foot examination 
d) Blood pressure to be lowered to below 130/80mmHg 
e) Add statin therapy as primary prophylaxis (SEMDSA, 2010, ADA, 2009) 
1.7 Non-specialist versus specialist care in diabetic patients 
Audits on the quality of care and cardiovascular risk parameters in diabetics have shown 
varying degrees of success in reducing complications. An audit on a 100 patients at each 
of the hospitals, King Abdulaziz Medical City (KAMC) in Riyadh and Diana Princess of 
Wales Hospital (DPWH) in Grimsby, United Kingdom showed that BP, HbA1C, lipids 
and urine dipstick were performed in 95%, 89%, 84% and 51% at KAMC and 100%, 
85%, 92% and 95% at DPWH.  The NICE guidelines targets of systolic blood pressure 
(SBP), diastolic blood pressure (DBP), HbA1C and total cholesterol were achieved in 
53%, 55%, 18% and 54% at KAMC and in 46%, 39%, 35% and 71% at DPWH (Dirar et 
al., 2012).  British general practitioners reported that only 34% of Type-2 diabetics 
achieved a HbA1C of ≤7% (Fox et al., 2006).  In urban academic centres in the USA, 28% 
reached a HbA1C ≤7% HbA1C, 32% attained a LDL target below 2.6 mmol/l, and 19.9% 
achieved a blood pressure below 130/85 mmHg (McFarlane et al., 2002).  By contrast, an 
audit of the General Practice Unit of the University Of Hong Kong showed that 70-80% 
of their diabetic patients had a HbA1C ≤7. A cross-sectional study of diabetic patients 
treated by specialists 5 years apart in Malaysia showed that glycaemic control was 
unsatisfactory in many patients (mean HbA1C approximately 8%; fasting glucose 
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approximately 9 mmol/L), with lipids well-controlled but hypertension being poorly 
controlled. The majority (approximately 71%) of patients in both cohorts were treated 
with oral hypoglycaemic agents (OHA) and only 24% were on insulin therapy. The 
conclusion was that the demographic profile, glycaemic control and cardiovascular risk 
factors were remarkably similar in both their earlier and later cohorts.  They concluded 
that more concerted efforts are needed to increase diabetes awareness and education 
(Mohamed and Diabcare-Asia Study, 2008). 
In a South African study comprising of 300 patients at Kalafong Hospital, physician 
education programmes and a structured consultation schedule showed an improvement in 
quality of care in two clinics with similar patient characteristics. The duration of the 
doctors consultation time increased but the number of annual visits for each diabetic 
patient was decreased. This study however did not show a significant change in HbA1C 
levels (van Zyl and Rheeder, 2004). 
In 2009, a cross sectional study of 150 patients from three tertiary hospitals in Gauteng, 
South Africa was conducted to determine the level of control in patients with Type-2 
diabetes.   The mean HbA1C was 8.7%, 25% of patients had SBP ≤130mmHg, 16% had 
DBP ≤80mmHg.  Fifty one percent of patients were on aspirin.  That study did not state 
whether the patients were on oral therapy alone or OHA plus insulin (Klisiewicz and Raal, 
2009). 
The above audits show disparate degrees of glycaemic control and other cardiovascular 
risk parameters among ethnic groups with different levels of health care.  
The treatment profile of patients in the above mentioned audits were either patients on 
OHA alone or OHA with insulin.  
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An audit measuring parameters of control in the same insulin-requiring diabetic 
population treated by non-specialist versus specialist-supervised care over two different 
periods has, to date, not been reported in the literature.  
Whether the glycaemic control and other cardiovascular risk parameters in Type-2 
diabetic patients differ under non-specialist versus specialist has not, to date, been 
addressed.  
1.8 Care of diabetic patients at the CHBAH 
Chris Hani Baragwanath Academic Hospital (CHBAH), is one of the world’s largest 
hospitals with 2888 beds, located in the huge sprawling township of Soweto (estimated 
population of 1.5 million), which is the largest urban population of Black Africans in 
Southern Africa. Soweto is, by and large, an economically disadvantaged township. 
Prior to September 2009, Type-2 diabetic patients at CHBAH were managed by junior 
doctors, medical officers and registrars of the Department of Internal Medicine.  After 
September 2009, a change towards specialist care (i.e. diabetologist, medical registrars or 
fellows under the supervision of an endocrinologist) was initiated. Patients were assessed 
on average 4-6 times a year, usually by a different doctor at each visit. Diabetic patients 
not requiring insulin are referred to primary health care facilities (i.e. Soweto Clinics) and 
only insulin-requiring patients are now treated at the Diabetes Clinic at CHBAH.  
1.9 Audits of diabetic files 
Unpublished data previously collected by myself at the Diabetes clinic in the years 2005-
2007 showed that the average HbA1C in the 905 patients was 10.28%.  The mean known 
duration of diabetes was 10.27 years. Ninety percent of patients were on insulin.  The 
percentage of patients who had hypertension was 87.7%, of which only 30.5% had SBP 
<130mmHg, and 47.5% a DBP <80mmHg.  The mean, SBP was 143mmHg and DBP 
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79.5mmHg.  Only 53.2% of patients had been on low-dose aspirin (150mg) and 31.0% 
on a statin for primary prophylaxis of CVD.  The local guidelines for Type-2 diabetes 
management at the time set the following goals:  
a) HbA1C ≤7.0% 
b) BP ≤130/80mmHg  
c) Total cholesterol ≤5mmol/l 
While there could be many reasons for not achieving the guideline targets, the main 
reasons were longer duration of diabetes (10.27 years), older population (65.8years), lack 
of patient education, lack of staff, and inadequate resources.  The above data prompted 
the need to study the differences, if any, in the parameters of control between the clinical 
care delivered by medical registrars and medical officers versus that under specialist 
supervision. 
1.10 Aims of the study: 
1. To perform a second audit of diabetic patients who were managed under 
supervised specialist care (from September 2009 to September 2012).   
2. To compare parameters of control (i.e. HbA1C, BP, Total Cholesterol and BMI) 
in the two audits i.e. 2005-2007 and after supervised specialist care (2009-2012). 
3. To evaluate the use of anti-platelet and statin therapy as primary prophylaxis in 
the second audit.  
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CHAPTER 2 
2.0 SUBJECTS AND METHODS 
2.1 Patients 
In 2005, data was collected in 506 patients.  These patient were seen from 2005 to 2007, 
and comprised the first study period, audit 1.  In September 2009, 415 of the above - 
mentioned patients were still attending the diabetes clinic. The second study period, audit 
2, spanned September 2009 to September 2012.  Only 136 patients had adequate data 
spanning both study (audit) periods from 2005 to 2012 for data analysis.  The remaining 
370 patients had missing data, were lost to follow up, were referred to a local primary 
health care facility because their metabolic parameters were close to target, or in some 
instances may have died. 
Black South African Type-2 diabetic patients requiring insulin +/- OHA and attending 
the CHBAH diabetic clinic were assessed.  Patients who were seen over a 24 month 
period in both of the audit periods, and who had 80% of parameters available for both 
audit periods fulfilled these criteria. One hundred and thirty six Type-2 insulin-requiring 
diabetic patients were included in the study.  The patient variables that were assessed in 
both audits were: 
a) HbA1C  
b) Blood pressure  
c) Non-fasting total cholesterol  
d) BMI 
Use of antiplatelet and statin therapy, and waist circumference were assessed for the 
second audit only. 
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2.2 Methods 
2.2.1 HbA1C 
 Note that the method for measuring HbA1C changed between the two audits. During the 
first audit the HbA1C was measured using the Hitachi 917 machine. During the second 
audit, two methods were used, the Hitachi 917 and the DCA Vantage machine.  The DCA 
Vantage was introduced in the second quarter of 2011 as a point of care HbA1C 
assessment. The National Health Laboratory Service (NHLS) conducted a test to validate 
the two methods. Forty eight samples were used to assess HbA1C using both 
methodologies and a statistical analysis performed. Sixteen samples did not have absolute 
results using the DCA Vantage method and were not statistically analysed. The remaining 
32 samples were analysed by Deming regression and Altman-Bland difference test 
methods.  The regression statistics showed the following:  Multiple R= 0.990350691, R2 
= 0.9807944491 with a standard error of 0.423371898.  The Y intercept was -0.415 and 
the slope 1.045984006.  This conversion factor was utilized to standardize any variation 
in the HbA1C results during the second audit period.   
2.2.2 Blood pressure 
The blood pressure and pulse were measured electronically by nursing staff over both 
audit periods.  The blood pressure was measured using a Dinamap Pro 100 (Orimax) for 
the first audit.  The hospital tender for the blood pressure machines were subsequently 
awarded to Welch Allyn, and the Welch Allyn Flexiport TM blood pressure machine was 
used for the second audit.  
2.2.3 Total Cholesterol 
The methodology utilised the Roche Hitachi Analyser. This remained the same between 
the years 2005 and 2012.   
16 
 
2.2.4 Body mass index (BMI) 
Height and weight were measured by nursing staff using an electronic scale, which 
measures both height and weight, during both audit periods. The BMI (wt/ht2) was 
calculated for each patient. In the first audit waist circumference was measured by the 
treating doctor and it was measured by either one of two nursing staff over the second 
audit period using the same brand of measuring tape. 
2.3 Statistics 
Values were retrieved from patient records and loaded into a Microsoft Excel spreadsheet 
for data cleaning and coding. Missing values were retrieved from new files, the laboratory 
database or archives.  If key variables, such as the first HbA1C of each study period, were 
not available, the patient was excluded.  If 80% of the total variables measured, but always 
including HbA1C, were available, that patient was included.  The data was imported from 
the Microsoft Excel spreadsheet to a statistical package (e.g. STATA version II) for the 
purpose of analysis. A descriptive analysis was used to describe the demographic 
characteristics of the patients.  Mean and standard deviation were calculated.  Categorical 
variables such as gender, use of aspirin and statins had their percentages calculated.  A 
paired t-test was used to compare the mean BP, weight, BMI, HbA1C and total cholesterol 
at the beginning and end of each audit period, and the mean of the variables between the 
two audits.  Ancova was used to adjust for baseline differences and regression in audit 1 
and 2.  X2 (Chi-square test) was used to report the percentage of patients that attained 
target variables at the end of each audit and McNemar test for paired proportions to 
ascertain if this difference in proportions is statistically significant or not.  
Results were considered significant if the P value was <0.05.
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CHAPTER 3 
3.0 RESULTS 
3.1 Clinical Characteristics 
The patients enrolled in this study were of African descent and of the 136 patients with 
Type 2 diabetes, 94 (69.12%) were female.  The mean age of patients was 65.8 years and 
the mean duration of diabetes was 14.67 ± 7.8 years. 
3.2 Audit One 
The characteristic of audit one are listed in Table 2.   
Table 2. Metabolic Parameters of control in Type-2 diabetic patients over a 24 month 
follow up period between January 2005 and December 2007 i.e. Audit 1 
Variable n Start SD min max n End SD min max 
HbA1C % 131 10.05 2.85 5.5 18.5 132 9.49 2.37 5.7 15.3 
SBP  mmHg 125 140.02 24.65 95 202 126 148.89 23.83 105 216 
DBP mmHg 113 78.42 11.90 60 110 121 80.35 11.88 60 114 
T Chol mmol/L 100 4.71 1.24 1.6 9.4 112 4.61 1.21 1.8 9.4 
BMI wt/ht2 102 32.93 7.19 16.76 52.28 102 33.74 7.49 21.76 55.91 
Weight kg 109 85.60 18.70 50 137.2 108 87.64 19.28 53.6 152.2 
n=number; SD=standard deviation; min=minimum value; max=maximum value 
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3.3 Audit Two 
The characteristic of audit two are listed in table 3.  
Table 3 Metabolic Parameters of control in Type-2 diabetic patients over a 24 month 
follow up period between September 2009 and September 2012 i.e. Audit 2 
Variable n Start SD min max n End SD min max 
HbA1C % 132 10.37 2.72 5.6 18.2 134 8.24 1.83 5.3 13.6 
SBP  mmHg 122 145.4 21.64 104 224 127 142.43 22.32 90 199 
DBP mmHg 117 82.69 12.09 60 126 124 81.19 10.71 63 116 
T Chol mmol/L 114 4.67 1.54 1.7 11.5 92 4.77 1.49 1.3 9.4 
BMI wt/ht2 111 34.13 8.03 19.77 67.37 123 34.11 8.00 18.59 62.08 
Weight kg 117 89.61 21.63 53 183.4 129 89.56 21.22 47 169 
Waist 
(F) 
cm      78 105.87 13.82 78 155 
Waist 
(M) 
cm      35 106.69 16.03 82 168 
n=number; SD=standard deviation; min=minimum value; max=maximum value; 
F=Female; M=Male 
 
3.4 HbA1C 
The changes in HbA1C over a 24 month treatment period for both audits are shown in 
table 4.  In audit one, the paired t-test shows a significant fall (p<0.0177) in HbA1C from 
baseline (10.08 ± 2.87%) to 24 months (9.47 ± 2.39%).  Audit two showed an even larger 
fall (p<0.0001) in HbA1C from baseline (10.34 ± 2.71%) to 24 months (8.26 ± 1.84).  The 
mean HbA1C achieved at the end of both audits are shown in table 5.  The specialist-
supervised study period (audit two) showed a great fall in achieved HbA1C to 8.22 ± 1.8% 
(95% CI 7.91 – 8.53; n=131) as compared to audit one 9.48 ± 2.37% (95% CI 9.07 – 9.89; 
n=131).  This difference was significant (p<0.0001).    When adjusting for baseline values 
of HbA1C Ancova shows the difference in the end HbA1C in both audits to be highly 
significant (F 32.96, p<0.0001) (Table 6).  Figure 6 shows the percentage of patients that 
reached a target HbA1C ≤7%, 17.56% at the end of audit one as compared to 29.85% at 
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the end of audit two.  The McNemar test showed this difference to be significant (exact 
sig (2-tail) 0.017) (Table 7). 
Table 4. Paired t-test from the beginning to the end of both 24 month audit periods for: 
HbA1C (%); Systolic Blood Pressure (mmHg); Diastolic Blood Pressure (mmHg); Total 
Cholesterol (mmol/L) and BMI (wt/ht2) 
Audit Variable* n Mean SD CI p value 
1 
HbA1C 1 128 10.08 2.87 9.58 – 10.58 
0.0177 
HbA1C 2 128 9.47 2.39 9.05 – 9.89 
Diff 128 0.61 2.87 0.11 – 1.11  
2 
HbA1C 3 131 10.34 2.71 9.87 – 10.81 
0.0001 
HbA1C 4 131 8.26 1.84 7.94 – 8.58 
 Diff 131 2.1 2.09 1.72 – 2.44  
1 
SBP 1 118 139.31 24.15 134.90 – 143.71 
0.0023 
SBP 2 118 147.72 23.53 143.43 – 152.01 
Diff 118 -8.42 29.27 -13.75 – -3.08    
2 
SBP 3 115 145.58 21.35 141.64 – 149.53 
0.1630 
SBP 4 115 142.57 22.91 138.34 – 146.81 
Diff 115 3.01 22.98 -1.24 – 7.25  
1 
DBP 1 103 78.19 12.21 75.81 – 80.58 
0.1326 
DBP 2 103 80.37 11.73 78.08 – 82.66 
Diff 103 -2.18 14.56 -5.02 – 0.67  
2 
DBP 3 107 82.72 11.54 80.51 – 84.93 
0.2906 
DBP 4 107 81.42 10.67 79.38 – 83.47 
Diff 107 1.3 12.65 -1.13 – 3.72  
1 
TChol 1 85 4.76 1.27 4.49 – 5.04 
0.0729 
TChol 2 85 4.58 1.15 4.33 – 4.82 
Diff 85 0.19 0.95 -0.02 – 0.39  
2 
TChol 3 81 4.86 1.72 4.49 – 5.24 
0.497 
TChol 4 81 4.78 1.54 4.44 – 5.12 
Diff 81 0.08 1.11 -0.16 – 0.33  
1 
BMI 1 89 33.05 7.47 31.48 – 34.62 
0.0062 
BMI 2 89 34.22 4.59 32.62 – 35.82 
Diff 89 -1.17 3.92 -2.0 – -0.34  
2 
BMI 3 107 34.12 8.12 32.56 – 35.67 
0.096 
BMI 4 107 33.78 8.15 32.22 – 35.34 
Diff 107 0.34 2.08 -0.06 – 0.73  
*In the variable column: 1=beginning of Audit 1; 2=end of Audit 1; 3=beginning of Audit 
2; 4=end of Audit 2; n=number; SD=standard deviation; CI=95% confidence interval; 
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Table 5. Paired t-test of the means achieved at the end of both 24 month audits for: HbA1C 
(%); Systolic Blood Pressure (mmHg); Diastolic Blood Pressure (mmHg); Total 
Cholesterol (mmol/L) and BMI (wt/ht2) 
Audit* Variable n Mean SD CI p value 
1 HbA1C (%)  131 9.48 2.37 9.07 – 9.89 
0.0001 
2 HbA1C   131 8.22 1.8 7.91 – 8.53 
 Diff 131 1.26 2.26 0.87 – 1.65  
1 SBP (mmHg)  118 148.65 23.93 144.29 – 153.02 
0.0197 
2 SBP       118 142.56 22.50 138.46 – 146.66 
 Diff 118 6.09 27.99 0.99 – 11.20  
1 DBP (mmHg)  111 80.75 11.99 78.49 – 83.00 
0.6301 
2 DBP   111 81.42 10.77 79.40 – 83.45 
 Diff 111 -0.68 14.74 -3.45 – 2.10  
1 TChol (mmol/L) 78 4.77 1.31 4.47 – 5.06 
0.4513 
2 TChol       78 4.88 1.55 4.54 – 5.23 
 Diff 78 -0.12 1.36 -0.42 – 0.19  
1 BMI (wt/ht2)  100 33.73 7.49 32.25 – 35.22 
0.4723 
2 BMI       100 33.93 7.96 32.35 – 35.51 
 Diff 100 -0.20 2.70 -0.73 – 0.34  
*In audit column: 1=end of Audit 1; 2=end of Audit 2;  n=number; SD=standard 
deviation; CI=95% confidence interval  
 
Table 6. Stats from ANCOVA comparing final values for each audit after adjustment for 
the respective baseline values  
Audit Variable Means n SD SE F p value 
1 HbA1C (%)  9.469531 128 2.389760 
1.837123 32.9613 0.000000 
2 HbA1C   8.259542 131 1.842439 
1 SBP (mmHg)  147.7203 118 23.53281 
21.84883 6.4669 0.011647 
2 SBP       142.5739 115 22.90524 
1 DBP (mmHg)  80.36893 103 11.72478 
10.69454 0.0268 0.870042 
2 DBP   81.42056 107 10.66827 
1 Chol (mmol/L)  4.576471 85 1.145555 
.9067063 0.9352 0.334945 
2 Chol       4.780247 81 1.544378 
1 BMI (wt/ht2)  34.21645 89 7.591854 
3.014020 10.891 0.001151 
2 BMI       33.77999 107 8.149179 
1=End value of Audit 1; 2=end value of Audit 2; n=number; SD=standard deviation; 
SE=standard error; F=Ancova 
 
3.5 Systolic Blood Pressure 
The changes in SBP over a 24 month treatment for both audits are shown in table 5.  The 
paired t-test shows a significant rise (p<0.0023) in SBP from baseline (139.31 ± 
24.15mmHg) to 24 months (147.72 ± 23.53mmHg) in audit one.  The SBP was essentially 
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no different from baseline (145.58 ± 21.35mmHg) to 24 months (142.57 ± 22.91mmHg) 
in audit two.  The mean SBP achieved at the end of both audits are shown in table 5.  
Audit two showed a greater fall in achieved SBP 142.56 ± 22.5mmHg (95% CI 138.46 – 
146.66; n=118) as compared to audit one 148.65 ± 23.93mmHg (95% CI 144.29 – 153.01; 
n=118).  The difference was significant (p<0.0197) on paired t-test and after adjusting for 
baseline differences using Ancova (F=6.47, p<0.012) (Table 6).  The percentage of 
patients that reached a target SBP <130mmHg was 20.63% at the end of audit one as 
compared to 29.13% at the end of audit two as shown in figure 7.  The McNemar test 
confirmed this difference to be significant (Table 7). 
3.6 BMI 
The changes in BMI over a 24 month treatment period for both audits are shown in table 
4.  The paired t-test shows a significant rise (p<0.0062) in BMI from baseline (33.05 ± 
7.47kg/m2) to 24 months (34.22 ± 4.59kg/m2) in audit one.  The BMI was essentially no 
different from baseline (34.12 ± 8.12kg/m2) to 24 months (33.78 ± 8.15kg/m2) in audit 
two.  The mean BMI achieved at the end of both audits are shown in table 5 where the 
paired t-test showed a non-significant difference (p<0.47), however the difference was 
significant when adjusting for baseline using Ancova (F=10.89, p<0.001) (Table 6). 
3.7 Aspirin Use 
One hundred and twenty seven of the 136 patients (93.4%) were on aspirin for primary 
prophylaxis for CVD at the end of audit two. 
3.8 Statin Use 
Ninety one of the 136 patients (66.9%) were on a statin at the end of audit two. 
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Figure 6. Percentage of patients with target HbA1C <7.0% 
 
 
 
Figure 7. Percentage of patients with target Systolic Blood Pressure <130 (mmHg) 
achieved at the end of both audits 
 
17.56% 
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Figure 8. Percentage of patients who achieved target Diastolic Blood Pressure <80 
(mmHg) at the end of both audits 
 
Figure 9. Percentage of patients who achieved a Total Cholesterol <4.5 (mmol/L) 
 
Table 7. McNemar Test comparing the percentage of patients that have reached targets 
of HbA1C, SBP, DBP and Total Chol. between the end of Audit 1 and 2 
 HbA1C 2-4 SBP 2-4 DBP 2-4 Chol 2-4 
N 122 118 111 78 
Chi-Squareb  1.531 .024 .593 
Asymp. Sig.  .216 .877 .441 
Exact Sig. (2-tailed) .017c    
b= Continuity Corrected; c=Binomial distribution used; 2=end of Audit 1; 4=end of Audit 
2 
 
 
  
47.11% 47.95% 
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CHAPTER 4 
4.0 DISCUSSION 
4.1 HbA1C 
In this audit of patients on combined oral hypoglycaemic agents and insulin therapy, the 
means of the HbA1C values in 131 patients at the beginning of Audit 1 and in 132 patients 
in Audit 2 were 10.05 ± 2.85% and 10.37 ± 2.72%, respectively (Table 2).  Our study 
group was not comparable to most American and European cohorts.  The Steno-2 study 
showed a baseline HbA1C of 8.4 ± 1.6% in their intensive therapy group (Gaede et al., 
2008).  The large difference in HbA1C levels is probably a result of the differences 
between the two population groups, in that our patient group and that of the Steno-2 study 
had different demographic profiles.  Our patients were somewhat older, with an average 
age of 65.8 years, as opposed to 55 years in the Steno-2 study.  Another variable is that 
the patient burden per health care provider and available treatments vary between 
different hospitals and countries. The larger SD in this audit versus that in the Steno study, 
may be the result of the greater range in duration of the diabetes, and thus reflect a wider 
variation in residual Beta-cell function, and also, perhaps, disparities in treatment 
delivered by different healthcare providers in our cohort.  The baseline HbA1C in our 
cohort was much higher than that reported by the Diabcare Africa study, i.e. 8.7 ± 2.5%, 
7.7 ± 2.2%, and 8.1 ± 2.3%, respectively for East, Central and West Africa.  This is 
probably as a result of the patient demographics in the Diabcare Africa cohort (Sobngwi 
et al., 2012).  The mean duration of illness was less, at 8.0 ± 6.0 years in the Diabcare 
study versus 14.67 ± 7.8 years in our study (Table 2).  The mean BMI was also less in the 
Diabcare at, 27.6 ± 5.6kg/m2 versus 32.93 ± 7.19 kg/m2 in our study. Furthermore, 88% 
of the 2352 patients in the Diabcare cohort were on oral agents alone.  
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The second objective of this study was to note the changes in mean HbA1C after a 24 
month follow up in each of the audits.  In the first audit (where the patients were managed 
by registrars and medical officers) the difference in HbA1C was significant with a mean 
HbA1C of 10.05 ± 2.85% at the start vs. 9.49 ± 2.37%, at the end (Table 2).  The paired 
t-test in 128 patients showed a difference of 0.61% (Table 4).  The second audit had a 
mean HbA1C at the start of 10.37 ± 2.72% vs. 8.24 ± 1.83% at the end (Table 3), with the 
paired t-test demonstrating a difference of 2.12 ± 2.09% (Table 4).  Both of these results 
were highly significant. Whilst the UKPDS study showed that the trend in HbA1C is 
upwards in both their conventionally and intensively treated groups, this audit showed a 
significant improvement despite the longer duration of the diabetes, higher BMI and, 
presumably, more advanced Beta-cell failure (UKPDS-Group, 1998b).  The improvement 
in the second audit was likely as a result of a longer duration in consultation time (while 
this was not measured directly, in Audit 1 the registrars managed between 35 and 50 
patients in a 4 hour period, whereas in Audit 2, 10 patients were seen during a minimum 
of 2 hours), the better diabetes care facility and the availability of specialist supervision.  
Both audit periods had the same diabetes educator cohort and education programme.  A 
dedicated full-time podiatrist was available during Audit 2.  Ophthalmologists were also 
available in a separate section of the hospital for the first audit, whereas for the second 
audit, a non-mydriatic fundal camera for eye assessment was available at the clinic itself.  
Both the dedicated availability of a podiatrist and retinal camera may influence 
complications outcome but would not influence the HbA1C.  The differences in HbA1C 
at the end of both audits may be due to the improvement in the quality of clinical care 
delivered by the health care provider.   
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Another objective was to note the difference in the mean HbA1C achieved at the end of 
each treatment period. The mean HbA1C in 131 patients at the end of Audit 1 and Audit 
2 was 9.48 ± 2.37 and 8.22 ± 1.8%, respectively (Table 5).  The paired t-test showed a 
significant difference of 1.26 ± 2.31% (p≤ 0.0001).  When baseline values for both audits 
are adjusted for, using Ancova: the difference between the final HbA1C values between 
the two audits are still highly significant F= 32.96 and p<0.0001 (Table 6).  Both the 
lower HbA1C and the narrower SD in the latter group reflect a meaningful improvement 
in level of care over and above the aforementioned reasons for this possible difference. 
This result is comparable to the Malaysian study, in which the patients were treated by 
specialists, where the mean HbA1C over a five year period remained approximately 8%, 
the major difference between these studies is that the Malaysian cohort was 
predominantly treated with oral agents (71%), thus indicating a less advanced (severe) 
diabetes (Mohamed and Diabcare-Asia Study, 2008). 
The percentage of patient that reached a target of 7.0% or lower at the end of Audit 1, as 
per SEMDSA and ADA guidelines, was 17.56% (23 of 131 patients) (SEMDSA, 2010, 
ADA, 2009).  This increased to 29.85% (40 of 134 patients) at the end of Audit 2.  The 
McNemar test for paired proportions showed this difference to be significant.  The 
binomial distribution was 0.017.  These results were achieved in spite of the average 
duration of illness for each patient now being at least five years longer. 
This improvement is in line with the percentage of patients that had achieved a HbA1C 
below 7.0% in the British General Practitioners audit of 24%, in the KAMC audit of 35%, 
28% in the urban academic centres in the USA, and only 18% in the DPWH audit in 
Riyadh (Fox et al., 2006, Dirar et al., 2012, McFarlane et al., 2002). 
The improvement in glycaemic control of the diabetes may be a result of: 
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1) The longer consultation time in Audit 2 vs Audit 1 and, consequently, a lesser 
patient load per doctor. 
2)     The on-site availability of a senior specialist to assist the non-specialist doctors 
during Audit 2.   
3) The introduction of point-of-care HbA1C measurements with its inherent 
advantages which was only introduced late in Audit 2 and is thus less likely to have 
influenced the fall in HbA1C. 
4.2 Blood Pressure 
The BP targets, as per SEMDSA and ADA guidelines, for the two Audits was a BP 
<130/80mmHg (SEMDSA, 2010, ADA, 2009). The patient characteristics in 1148 Type-
2 diabetic patients with hypertension in the UKPDS were a mean age of 56 years, BMI 
of 29kg/m2, and a BP 160/94mmHg.  That study showed that a 10mmHg drop in SBP 
was much more beneficial than a reduction in HbA1C from 8% to 7.1% in reducing all 
macro- and micro- vascular outcomes (UKPDS-Group, 1998a, UKPDS-Group, 1998b).  
“Tight control” equated to a mean of 144/82mmHg vs “non-tight control”, 154/87mmHg.  
There were benefits seen in stroke i.e. 44% reduction (p=0.013); diabetes related death 
32% reduction (p=0.019); diabetes related end-points 24% reduction (p=0.0046); 
microvascular endpoints of 37% reduction (p=0.0092); and heart failure 56% reduction 
(p=0.0043). A 21% reduction in myocardial infarction was the only outcome that was not 
significant (p=0.13). 
The mean BP in a Cameroonian cohort of 308 Type-2 diabetic patients was 
142.7/83.7mmHg.  Compared to the their cohorts’ baseline, the mean baseline BP in our 
cohort was lower.  The mean SBP in 125 patients at the start of audit 1 was 140.02 ± 
24.65 mmHg and in 113 patients a DBP of 78.42 ± 11.9 mmHg (Table 2).  This was in 
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spite of the higher BMI 32.93 ± 7.19 kgm2   (Table 2) and longer duration of diabetes in 
our subjects. 
Furthermore, our BP outcome was comparable to the Diabcare Africa Study which had a 
mean SBP of 139.0 ± 24.0mmHg and a mean DBP of 82.0 ± 13.0mmHg (Sobngwi et al., 
2012).  The SBP during Audit 1 in our cohort showed a significant worsening (p value of 
0.0023, Table 4) over the 24 month period, and is consistent with many studies in Type-
2 diabetic patients.  Reasons cited for this increase in BP are progression of the underlying 
disease, progressive increases in weight, and lower levels of activity with age.  However, 
these likely do not apply to our patients as Audit 2 showed an improvement in both SBP 
and DBP, albeit not statistically significant (Table 4). 
When the mean SBPs achieved at the end of each Audit were compared, the paired t-test 
showed a significant improvement, at the end of Audit 2 vs. the end of Audit 1.  The 
difference was 6.09mmHg (p ≤0.0197) (Table 5).  Adjusting for baseline SBP in both 
audits using Ancova, the difference was still significant, F=6.467 and p<0.012 (Table 6).  
The mean DBP achieved at the end of each Audit showed good control but no significant 
difference was demonstrated (Table 5 and 6).  The percentage of patients that achieved a 
target SBP <130mmHg increased from 20.63% in Audit 1 to 29.13% in Audit 2.  This 
was however not significant when employing the McNemer test (Table 7), but this was 
better than the 21% achieved in the Diabcare cohort (Sobngwi et al., 2012).  The 
previously mentioned KAMC and DPWH cohorts showed that 53% and 46% of patients 
reached target SBPs respectively.  Both of these studies have demonstrated the need to 
intensify efforts in achieving better SBP control. 
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4.3 Total Cholesterol 
The CARD study showed that in Type-2 diabetic patients, primary prevention with statins 
is a viable and cost effective intervention (Colhoun et al., 2004). Whilst no equivalent 
study has been performed in Southern African Black patients, the SEMDSA guidelines 
has the same target for total cholesterol as the ADA guidelines, i.e. below 4.5mmol/l, and 
has recommended statin use as primary prophylaxis (SEMDSA, 2010, ADA, 2009).  The 
mean total cholesterol (TC) at the beginning of Audit 1 was 4.71 ± in 1.24 mmol/l in 100 
patients and 4.61 ±1.21 mmol/l in 112 patients at the end of Audit 1.  When comparing 
the difference in the mean in 85 patients from the beginning to the end of Audit 1, the 
difference was a fall of 0.187 ± 0.95mmol/l, but was not statistically significant  (Table 
4). 
 
The paired t-test was used to compare the mean TC at the beginning to the end of Audit 
2 in 81 patients, the levels were 4.86 ±1.72 mmol/l and 4.78 ±1.54 mmol/l, respectively.  
The mean difference was 0.084 ± 1.11 mmol/l, which was not statistically significant. 
(Table 4) 
An objective of this study was to assess the difference in the TC achieved at the end of 
both audits.  A total of 78 patients were compared.  The mean at the end of Audit 1 was 
4.77 ± 1.31mmol/l and at the end of Audit 2 was 4.88 ±1.55 mmol/l.   Although the trend 
in mean TC was worse, the p value (<0.45) was not significant. (Table 5) This was 
confirmed using Ancova (F=0.935 and p≤0.34). (Table 6) 
The percentage of patients that achieved TC below 4.5mmol/l were comparable in both 
Audits at 47.11% and 47.95%, respectively. (Figure 9)  These results were comparable to 
the Diabcare cohort where the mean was 4.9 ± 1.2mmol/l and KAMC cohort in which 
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54% reached a target cholesterol of lower than 4.5mmol/l (Sobngwi et al., 2012, Dirar et 
al., 2012).  However, our study population had much lower starting TC levels than the 
cohorts studied in the UK and Ireland which are considered developed nations (Colhoun 
et al., 2004).  Given that there are currently no restrictions in the use of statins at CHBAH, 
one would expect that more than 66.4% of our cohort to have been on statins. 
4.4 BMI 
The concept of BMI originated from the insurance industry in the Netherlands.  The 
SEMDSA, ADA and IDF criteria all use BMI to assess obesity.  Normal BMI is 18 to 25 
kg/m2, overweight being 25.1 to 29.99 kg/m2, obese  30-34.99 kg/m2, and morbidly obese 
35-39.99 kg/m2 (SEMDSA, 2010, ADA, 2009, IDF, 2009). 
The average BMI at the beginning Audit 1 in 102 patients was 32.93 ± 7.19 kg/m2, and 
rose to 33.74 ± 7.49 kg/m2.  For Audit 2, 111 patients at the beginning of the period had 
a BMI of 34.13 ± 8.03 kg/m2 and at the conclusion of Audit 2 was 34.11 ± 8.00 kg/m2 in 
123 patients.  The difference in the mean in Audit 1 was 1.17 ± 3.92 kg/m2, which was 
significantly worse with a p value <0.006.  The difference in means in Audit 2 was only 
0.337 ± 2.08 kg/m2.  However, this fall was minimal and was not significant.  (p< 0.096). 
The result was, however, gratifyingly unexpected as most studies have shown a continued 
increase in weight in all Type-2 diabetic patients other than those being treated with 
metformin alone. 
After adjusting for baseline differences in BMI, Ancova showed a significant worsening 
between the end results achieved at the end of both audits, the F=10.891; p<0.0012 (Table 
6).  Currently, SA has an epidemic in obesity (Swinburn et al., 2011).  This may adversely 
affect the attainment of HbA1C and BP targets.   
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4.5 Aspirin Use For Primary Prophylaxis 
The use of low dose aspirin for primary prophylaxis in Type-2 diabetes is well 
documented (De Berardis et al., 2009) and its use in the diabetic clinic at CHBAH has 
increased markedly from 53.2% in 2005(Audit 1) to 92.7% in 2012 (the end of Audit 2). 
4.6 Lipid Lowering Agents for Primary Prophylaxis 
In 2005, a mere 31% patients were on a statin, but this increased to 66.67% by 2012.  This 
is still sub-optimal. However, many of our patients have TC levels below 3.5mmol/l and 
LDC levels below 1.5mmol/l and may not require such interventions.  Although the 
guidelines encourage statin use, these patients often are not prescribed statins.  One may 
deduce from the JUPITER study that achieving lower LDL levels has cardiovascular 
benefits (Ridker et al., 2009). However, no studies have yet been undertaken in South 
African Black diabetic patients who generally have low TC and LDL levels. 
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CHAPTER 5 
5.0 CONCLUSION 
This study demonstrates that there was a meaningful and beneficial difference in the level 
of care delivered by doctors working in an endocrinologist/diabetologist supervised clinic 
(ESC) as compared to a “registrar-driven” Type-2 diabetes clinic (RDC).  While both 
groups achieved a statistically significant improvement in HbA1C, the ESC managed a 
2.1 percentage point difference in HbA1C which was significantly better than in the RDC, 
which will hopefully translate into a reduction in micro-vascular complications, as in 
UKPDS. 
The percentage of patients reaching a target of HbA1C of 7% was 29.85% in the ESC as 
compared to 17.56% in the RDC. 
While it has been recognised that patients with Type-2 diabetes often have refractory 
hypertension with at least 2-3 drugs being required to control the BP, this study showed 
that SBP improved in the ESC and that more patients achieved a target SBP below 
130mmHg and diabolic BP below 80mmHg than the RDC. 
Weight remained unchanged during the RDC study period but tended to improve in the 
ESC.  BMI had significantly changed from the end of Audit 1 to 2. 
The percentage of patients on aspirin and a statin for primary CVD prophylaxis increased 
from the beginning of Audit 1 through to the end of Audit 2. 
5.1 Future Considerations 
This study shows that there are avenues that may need to be explored to improve control.  
Blood pressure, in particular, remains a tough challenge and future studies in this 
population group need to explore the use of combination therapies, patient education 
programmes on dietary strategies, improving physical activity and especially weight 
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reduction as a means of improving BP and other important parameters that impact on 
CVD morbidity and mortality.   
5.2 Limitation of this study 
1) The number of patients studied are relatively small 
2) Important CVD biochemical markers and complication have not been evaluated, 
nor their relationship to HbA1C, BP, BMI, weight, and waist circumference. 
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